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ABSTRACT 
 
INTRODUCTION 
 
Although much focus has been placed towards rapid scale-up of antiretroviral treatment 
programmes and interventions for the prevention of mother-to-child transmission of human 
immunodeficiency virus (HIV), very little is known about adherence to highly active 
antiretroviral therapy (HAART) and loss to follow-up of pregnant women in antiretroviral 
treatment programmes in the developing world.  In this retrospective cohort analysis, we 
described the baseline characteristics of adult women who were pregnant at the time of 
HAART initiation (pregnant at start) as well as women who became pregnant during follow-
up after starting HAART (pregnant after) and women who never had a pregnancy (not 
pregnant) during the study period.   We evaluated the association of pregnancy status with 
adherence and loss to follow-up in these three groups of women.   
 
MATERIALS AND METHODS 
 
Themba Lethu Clinic is an urban public-sector antiretroviral rollout facility in Johannesburg, 
South Africa.  A retrospective analysis was conducted of all adult women initiating HAART at 
this clinic between January 2005 and December 2007.  Clinical data from these patients was 
analysed for differences in rates of loss to follow-up, and measured adherence rates based 
on CD4 cell count response and virologic suppression. Regression models were performed 
to determine independent predictors of adherence and loss to follow-up and compared 
between the three groups. Survival analysis, in the form of Kaplan-Meier plots and log-rank 
tests, was used to compare the time to becoming lost to follow up. 
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RESULTS 
 
Between 1 January 2005 and 31 December 2007, 5129 women initiated HAART at Themba 
Lethu Clinic, Johannesburg, South Africa.  Of these women, 521 (10.0%) were pregnant at 
the time of HAART initiation (pregnant at start) and 291 (5.6%) became pregnant during 
follow-up (pregnant after).  Women who were pregnant at start (16.6%) of HAART had less-
advanced HIV disease than the not pregnant women and pregnant women after HAART 
initiation 4608 (89.9%). Overall pregnant women were significantly younger than the not 
pregnant women and fewer pregnant women had a CD4 <100 cells/mm3 and a WHO stage 
III of HIV disease.  There was no significant difference in the CD4 cell count response and 
virological suppression between the three groups of women based on pregnancy status at 6 
months and 12 months (X2=2.1, p=0.347 and X2=4.4, p=0.111 respectively). However, 
women pregnant at start were more likely to become lost to follow-up (X2=15.8, P=<.0001) 
during follow up.  In the multivariate Cox logistic regression model, independent predictors 
of loss to follow-up were pregnancy, baseline CD4 cell count and age at initiation.  Being 
pregnant was significantly associated with being loss to follow-up. 
 
CONCLUSIONS 
 
Pregnancy is significantly associated with defaulting treatment and becoming lost to follow-
up from HAART treatment programmes.  Together with being pregnant, young age and a 
low CD4 at baseline are high risk factors for non adherence and loss to follow-up in this sub-
group of the population.   Early initiation of HAART with adequate pre-treatment counselling 
and ongoing adherence support could help improve adherence and retention in care for 
patients in treatment programmes in resource-limited settings.  Interventions to trace 
patients immediately upon missed appointments would help to reduce the number of 
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patients’ loss to follow-up.  Moreover, integration of tuberculosis (TB), antenatal care (ANC) 
and HIV treatment services may maximize the effectiveness of interventions aimed at 
reducing the loss to follow-up rate.  The initiation of HAART in pregnancy requires 
strengthened antenatal and HIV services that target women with advanced stage disease. 
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CHAPTER 1  INTRODUCTION  
 
1.1 BACKGROUND  
 
HIV/AIDS is one of the most challenging and serious public health crises that the world faces 
today.  According to the WHO 2008 statistics, AIDS has killed more than 25 million people 
since 1981 and it is estimated that 33.4 million people, including 2.1 million children, are 
now living with HIV (WHO, 2008).   Approximately 420, 000 children were newly infected in 
2007, of which more than 90% where from sub-Saharan Africa (UNICEF, 2007).  The 
overwhelming majority (90%) of HIV infected children acquire the infection through mother-
to-child transmission (MTCT) (UNICEF, 2008; WHO 2008).   
 
In 2008, sub-Saharan Africa accounted for 67% of HIV infections worldwide, 68% of new HIV 
infections among adults and 91% of new HIV infections among children. The region also 
accounted for 72% of the world’s AIDS-related deaths in 2008 (WHO, 2008). One of the 
worst affected countries in sub-Saharan Africa is South Africa.  It has more people living with 
HIV/AIDS than any other country in the world and has a higher HIV prevalence in females 
than males and an increasing rate in children (WHO, 2008).  Sub-Saharan Africa remains the 
region most heavily affected by HIV.   
 
Early in 2004, the South African National Department of Health began implementing the 
Comprehensive HIV and AIDS Care, Management and Treatment (CCMT) programme.  The 
CCMT programme affirmed the commitment of the South African government to slow down 
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the increasing number of HIV infections and AIDS related deaths across the country. 
Themba Lethu, the adult HIV Clinic at the Helen Joseph Hospital is a public hospital site of 
the National ARV programme.  Since April 2004, the clinic has been providing antiretroviral 
drugs through its CCMT programme to eligible adult patients according to the National 
Treatment Guidelines.  HIV-infected pregnant women eligible for ART treatment are 
referred to Themba Lethu Clinic by the Coronation Women and Children Hospital, located 
approximately 1 km away.  From the beginning of the programme, pregnant women eligible 
for ART presenting at the Themba Lethu Clinic have been “fast tracked” onto triple therapy.  
According to the National Treatment Guidelines, patients eligible for starting antiretroviral 
therapy need to be prepared via a series of screening visits for treatment readiness.  This 
process takes several weeks before the patient could initiate treatment.  Pregnant women 
with CD4 cell count of less than 200 cell/mm3 cannot wait 4 - 6 weeks to start treatment, 
but need to start immediately. When these pregnant women are referred to antiretroviral 
treatment sites with other adult patients already worked up and waiting for treatment, 
pregnant women need to “jump the queue”. The reason for fast tracking these women is to 
ensure optimal health of the pregnant mother and her unborn child.   
 
Maternal mortality has previously been due to direct obstetric causes such as haemorrhage, 
hypertension, and complications of unsafe abortion. This pattern is changing in many places 
as AIDS-related complications now account for a high proportion of maternal deaths 
(Bwirire et al., 2008; Mellins et al., 2008). AIDS defining illnesses like tuberculosis and other 
opportunistic infections are becoming the leading cause of maternal mortality (WHO, 2004).  
Most pregnant women present to the ARV clinic with low CD4 cell counts and almost in the 
third trimester of their pregnancy, therefore all efforts are made to ensure suppression of 
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HIV virus and disease progression so that chances of mother to child transmission are 
reduced.  Triple therapy has been found to be the most effective method of preventing 
mother-to-child transmission as it secures the health of the women and improves survival of 
the child (WHO, 2004).   
 
Since the implementation of the ART programme in 2004 almost 13 000 adult patients have 
been in care at the clinic, of whom approximately 9000 are currently on antiretroviral 
treatment.   Almost 60% of this group of adult patients on treatment are women with a 
mean age of 29 years.  
 
The introduction of highly active antiretroviral treatment has resulted in a significant 
reduction of the HIV virus and an increase in CD4 cell count.  In an evaluation by Coetzee et 
al (2004) noted that more women (70%) with a median age of 31 years assessed treatment.  
Evaluation of ART programmes have found improvement in clinical outcomes and a 
reduction in mortality rates (Coetzee et al., 2004; Wools-Kaloustain et al., 2006; Volmink et 
al., 2007).  However, long-term retention of patients on ART treatment programme is 
becoming increasingly challenging (Rosen et al., 2007; Lawn et al., 2006; Bisson et al., 2008).  
Poor adherence to highly active antiretroviral therapy and commitment to regular clinic 
attendance are growing concerns (Rosen et al., 2007; Lawn et al., 2006).   
 
Loss to follow-up is monitored closely at Themba Lethu Clinic and an initial evaluation has 
indicated that many of the patients who are lost to follow-up are pregnant women.  This 
raised the question as to whether loss to follow-up is associated with being pregnant. The 
loss to follow-up rate impedes the benefit of the programme and raises serious concerns 
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regarding the development of resistant mutations and the risk of vertical transmission 
(Zorilla et al., 2003; Bardeguez et al., 2008).   
 
In April 2007, the clinic introduced proactive tracing of patients who miss their antiretroviral 
collection appointment, using the contact telephone number provided by the patient.  In 
order to make contact, three calls are made at three different times on different days.  
However, a great majority of these people are untraceable.  It is challenging to keep up with 
patient’s changing contact details and addresses.  The clinic has therefore introduced the 
practice of updating the patients contact details and change of address at every visit.  
Patients not traced through three attempted telephone calls are referred to community 
health workers for a home-based visit.  Traced patients are counselled and encouraged to 
return to the clinic.  Patients traced and not found by community health workers are 
confirmed as loss to follow-up.  
 
Patient attrition is a major concern for ART programmes in sub-Saharan Africa (Rosen et al., 
2007; Brinkhof et al., 2008; Bwirire et al., 2008; Kaplan et al., 2008).  Although much efforts 
are made to make antiretroviral treatment accessible, commitment to long-term therapy 
and keeping up with regular follow-up visits has been particularly challenging for patients on 
antiretroviral therapy (Ive et al., 2005; Giordano et al., 2007; Carrieri et al., 2006).  Rates of 
loss to follow-up are extremely variable, with reported cumulative rates of up to 59% (van 
Oosterhout et al., 2005).   Many large cohorts have seen considerable losses to follow-up 
(LTFU) with high rates like 27-30% occurring in the first few months after initiating HAART 
(Nachega et al., 2006; Lawn et al., 2006; Rosen et al., 2007).  Moreover, it is becoming 
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increasingly difficult to follow the growing population of patients and to trace those who do 
not return to the clinic (Dalal et al., 2008; Brinkhof et al., 2008). 
  
Losses to follow-up of pregnant women may threaten patient care as missing clinic 
appointments may have a negative influence on the health of these women leading to 
progression of disease and increasing vulnerability to opportunistic infections which may 
result in death (Bisson et al., 2006).  Poor adherence to ARVs during pregnancy can lead to 
increased risks of vertical transmission. These are serious concerns from a public health 
perspective.  
 
1.2 STATEMENT OF THE PROBLEM 
 
At Themba Lethu Clinic, monitoring and evaluation of the ART program revealed that large 
number of pregnant women were lost to follow-up soon after initiating HAART.  This raised 
a concern as to whether pregnancy is associated with poor adherence and becoming lost to 
follow-up.  
 
As the Health System Information Manager at the Themba Lethu Clinic, I have been involved 
with the input and monitoring of the clinical data.  I have over the years observed that a 
good proportion of the LTFU patients at the clinic are pregnant women.  This has inspired 
me to undertake the task to investigate the loss to follow-up of pregnant women at the 
Themba Lethu Clinic with the permission and support of the clinic’s Research Advisor.    
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1.3 JUSTIFICATION FOR THE STUDY 
 
Maternal health and reduction of vertical transmission are primary concerns for women 
with HIV infection.  With the widespread access to antiretroviral therapy, mother-to-child 
transmission has reduced significantly (Laine et al., 2000; Rodriguez et al., 2007). However, 
adherence and retention on treatment particularly pregnant women have proven to be 
serious challenges.  Pregnant women may experience additional physical, economic and 
emotional stress and this may influence their adherence patterns (Bardeguez et al., 2008; 
Laine et al., 2000).  Poor adherence in pregnant women causes great concerns regarding 
direct transmission of HIV to their unborn child.  Failure to commit to regular follow-up at 
the ART clinic may lead to disastrous consequences to the women’s own health, including 
the development of viral resistance, disease progression, and death (Bardeguez et al., 2008; 
Lain et al., 2000). Therefore, from a public health perspective the consequence of non 
adherence necessitates the need to improve maternal ART adherence and better retention 
strategies.     
Many women learn their HIV status for the first time during their antenatal visit. This leaves 
them with little time to digest the fact that antiretroviral therapy is a life-long process 
(Kaplan et al., 2008).  This research aims to get a better understanding of loss to follow-up in 
female ART patients and the impact of pregnancy on adherence and retention.   
 
This analysis will be important in patient management, especially in the context of large-
scale implementation of the ARV treatment programmes. It is expected that the findings 
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generated from this study will contribute to knowledge and understanding of non 
adherence and loss to follow-up and whether it has any association with being pregnant.  
The findings will also serve as a monitoring and evaluation tool for ART programmes and 
better tracing mechanisms to ensure long-term retention on treatment. 
 
1.4 STUDY OBJECTIVES 
 
The main objective of this study was to compare baseline characteristics and outcomes 
between different groups of women initiated on HAART at Themba Lethu Clinic from 1st 
January 2005 to 31st December 2007. We differentiated three groups of women based on 
their pregnancy status; namely women who initiated HAART because they were pregnant 
(‘pregnant at start’), women on HAART who later fell pregnant (‘pregnant after’), and 
women who did not have a pregnancy during the study period (‘not pregnant’).  
 
The specific research objectives were: 
1. To describe the baseline characteristics of women who were not pregnant, women 
pregnant at start and those that became pregnant after HAART initiation.  
2.  To compare the adherence and loss to follow-up rates between these women based 
on their pregnancy status. 
3. To compare the mortality experience of the three groups of women.   
4. To determine if the introduction of proactive tracing of patients in April 2007 
reduced the proportion of pregnant women lost to follow-up. 
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CHAPTER 2   LITERATURE REVIEW 
 
This chapter reviews some salient literature on adherence to antiretroviral treatment and 
loss to follow-up in pregnant women.  It begins by discussing adherence and its importance 
in an effort to understand the outcomes of poor adherence.  This is followed by the 
discussion on the complexities of adherence with regard to its measurement and prediction.  
Some predictors of adherence as highlighted in this literature review which leads to loss to 
follow-up are presented.   
 
2.1 INTRODUCTION 
 
Antiretroviral therapy is widely used in pregnant women and has shown to be highly 
effective in improving maternal health by reducing the progressive loss of CD4 cells that 
leads to severe immunodeficiency.  A decrease in CD4 cells below 200 cell/mm3 is the 
threshold where the risk of opportunistic infections increases (National Treatment 
Guideline, 2004).  Therefore, current management of HIV infections aims to prevent 
opportunistic infection and to reduce mortality by starting HAART before CD4 cells decline 
below the critical level (National Treatment Guideline, 2004).  In the case of pregnant 
women it is critical to suppress the progression of the disease and reduce the risk of mother 
to child transmission of HIV (UNAID, 2008).  However, inadequate adherence to 
antiretroviral therapy may result in a poor clinical and virologic outcome.   High HIV viral 
load may in turn increase infectivity of the patient and, thus, the probability of further 
spread of the infection, possibly with a drug-resistant virus (Bardeguez AD, 2008; Laine C, 
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2000).  Adherence to therapy can be one of the most important factors that contribute to 
the efficacy of the treatment (Nachega et.al, 2007).  However, little attention has been given 
to the relationship between adherence to antiretroviral therapy and pregnancy in sub-
Saharan Africa.   
 
Long-term adherence to antiretroviral therapy places extraordinary demands on patients, 
because they need to attend a clinic on a monthly basis to get medication.  The rate of 
missed monthly appointments and loss to follow-up is increasing rapidly.  Increasing 
numbers of loss to follow-up may lead to an underestimation of mortality. There is an 
urgent need to address the individual and public health consequences of non-adherence 
and retention in ART programmes.   
 
2.2 MONITORING ADHERENCE 
 
Adherence is defined as taking doses of drugs and sticking to the treatment plan. It means 
taking the correct dose of drugs at the correct time and in the correct way with correct 
dietary requirements (Ickovics and Meade, 2002).  Patients who do not adhere to their 
treatment plan eventually begin to miss their scheduled clinic visits.  If a patient misses 
three antiretroviral pick-up visits within 90 days after the last scheduled visit, the patient is 
considered loss to follow-up.     
 
Follow-up and adherence to ART are important measures of the performance of ART 
programmes. Adherence can be measured based on patient self-report (via interview, 
questionnaire), pill counts, electronic medication monitoring devices such as the 
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medication-event monitoring system, or pharmacy refill records.  Clinical and laboratory 
measures (viral load, CD4 cell count, urine analysis) are correlated with self-reports of 
adherence although failure of virological suppression can occur with perfect adherence 
(Djomand et al., 2003).  There are fears that resource limited countries are unable to ensure 
adherence to ART due to their weak health systems, lack of capacity and infrastructure, 
which impede the rapid expansion of ART programmes and services (Bekker et al., 2006; 
Brinkhof et al., 2008). 
 
2.3 FACTORS ASSOCIATED WITH NON-ADHERENCE 
 
Factors contributing to non-adherence and poor clinic attendance are multiple and complex.   
Many factors have been found to influence adherence to medication.  Bwirire et al (2008) 
identified the following reasons for loss to follow-up: not being adequately prepared, fear of 
stigma, discrimination, household conflict and even divorce on disclosure of HIV status, lack 
of social support, fear of breast feeding, long waiting hours at the clinic and inability to 
afford transport costs. When factors of adherence are scrutinized, two broad categories 
appears - factors related to the ARV regimen and factors related to the HIV-infected 
individual. 
 
2.3.1 Factors related to the ARV regimen 
 
One of the challenges of adherence to antiretroviral therapy is the complexity of the 
regimen, the strict dietary requirements, as well as the associated side effects (Ickovics and 
Meade, 2002).  The AIDS Clinical Trial Group 370 found that adverse side effects were the 
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strongest predictor of non-adherence (Ickovics and Meade, 2002).  Side effects of the 
treatment include but are not limited to diarrhoea, fatigue, nausea, vomiting, peripheral 
neuropathy and metabolic changes (Brinkhof et al., 2008; Laine et al., 2000; Bwirire et al., 
2008).  In the trial group, these side effects were found to occur in the first to the fourth 
week after initiation of HAART. (Ickovics and Meade, 2002). Difficulty ingesting large pills 
including heavy pill burden are also found to contribute to non-adherence (Bwirire et al., 
2008).  
 
2.3.2 Factors related to pregnant women 
 
Some studies have found an association between adherence and factors such as age, 
gender, race, economic status, educational level and literacy (Ickovics and Meade, 2002; 
Bwirire et al., 2008, Rosen 2007).  Knowledge and attitude to treatment and care-giving 
responsibilities have been found to be related to adherence (Carrieri et al., 2006; Weiser et 
al., 2003).   In addition, emotional, economical and physical stress as well as other demands 
that pregnant females experience may sway their patterns of adherence to HAART 
(Bardeguez et al., 2008; Laine et al., 2000).  Low-level of education and having a suspicion 
that the antiretroviral drug may harm the baby may impact negatively on some women. 
Fear of disclosure and wanting to avoid taking medication in the presence of family or 
friends, feeling depressed, hopeless, or overwhelmed may contribute to the predictors of 
non-adherence, especially in the case of pregnant women who has just known her HIV 
status (Mills et al., 2006).  Pregnant women may also encounter additional financial costs as 
they are required to visit the antenatal clinic as well as the ARV clinic on a monthly basis.  
Loss of income due to absenteeism from work, transport cost to and from the clinics, the 
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cost of user fees, long waiting hours and the burden of childcare during medical visits may 
discourage women from attending to their visits (Rosen et al., 2007; Mills et al., 2006).  
Other barriers include doubting the effectiveness of HAART, having a decreased quality of 
life; uncertainty of long-term effects and unwanted changes in body image (Mills et al., 
2006). 
 
There is currently little data on ARV adherence in pregnant and post-partum women. 
Majority of the studies that have been conducted were in resource-rich settings.  We 
reviewed adherence and loss to follow-up rates in general and compared the findings in the 
developed and the developing countries. 
 
2.4 COMPARISON OF ADHERENCE AND OUTCOMES IN LOW AND HIGH 
INCOME COUNTRIES 
 
In 2008, Brinkhof et al. used data from a network of treatment programmes in low-income 
countries to examine the early loss of patients starting HAART.  They found that only 3% of 
patients were known to have died by 6 months, but an average of 21% were lost to follow-
up by that time and 4% never returned after initiating treatment.  Brinkhof et al (2008) 
found that treating a maximum number of new patients has been the priority of many 
public sector programmes.  This implies that many sites find it increasingly difficult to cope 
with the growing patient population and to keep track of those not keeping up with their 
appointments. 
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Mills et al (2006) conducted a meta-analysis to evaluate estimates of adherence to 
antiretroviral therapy in sub-Saharan Africa and North America. The study found that 
favourable levels of adherence as measured through patient self-report could be achieved in 
the sub-Saharan Africa and suggested that concerns related to the expansion of the ART 
programme are unwarranted.  This was evident from the findings, which showed that from 
a pooled estimate of ART adherence in North America, 55% of patients achieved adequate 
levels of adherence compared to 77% of patients in sub-Saharan Africa (Mills et al., 2006).  
 
Similarly, correlates of adherence, namely viral load suppression and gain in median CD4 cell 
count has been shown to be similar in the developed and developing world. Pooled analysis 
of 30 treatment cohorts (18 from Africa, Asia and South America and 12 from Europe and 
North America) showed that 76% of patients in low-income countries compared to 77% in 
high income countries achieved viral load suppression after 6 months of being on ART (ART-
LINC and ARTCC Group, 2006).  The highest mortality occurred during the first few months 
after starting treatment, where 78% of deaths in low-income countries and 62% in high-
income countries occurred during the first 6 months. The higher mortality in low-income 
countries has been attributed to co-morbidities of TB and other opportunistic infections 
where access to prophylaxis, diagnostic facilities and effective treatment is often more 
limited (ART-LINC and ART-CC Group, 2006: 822).  In addition, the high mortality within the 
first few months on ART has been attributed to patients presenting with late stages of HIV 
disease (Mills et al., 2006, Rosen et al., 2007). There are a number of possible reasons why 
people test late, some of which are denial, stigma and confusing political statements 
(Ickovics and Meade, 2002; Bwirire et al., 2008, Rosen 2007).  Loss to follow-up of patients 
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during the first few months of being initiated on HAART was found to be 15% in low income 
countries compared to 5% in high-income countries (ART-LINC and ART-CC Group, 2006). 
 
2.5 ADHERENCE TO ANTIRETROVIRAL THERAPY IN PREGNANT WOMEN 
 
Antiretroviral therapy is widely used in pregnant women and has proven to be highly 
effective in the prevention of mother-to-child transmission (Turner et al., 2000; Bwirire et 
al., 2008).  The majority of studies that have been conducted on adherence in pregnant 
women are from resource-rich settings.   
 
Studies in the developed world that have examined adherence to antiretroviral treatment in 
pregnant women using self-reporting or pill counts as an adherence measure have indicated 
that adherence is much higher in pregnant versus not pregnant women (Bardefuez  et al., 
2008;  Mellins et al., 2008; Rodrigues et al., 2007).  
 
However, when more objective measures of adherence, such as pharmacy data or blood 
and urine assays were used, results indicated generally poor adherence in pregnant women 
(Laine et al., 2000; Demas et al., 2005). In an audit report, Kingston et al (2007) evaluated 
that age, ethnic origin and knowledge of HIV status prior to pregnancy did not appear to be 
factors contributing to non-adherence but being treatment naïve and poor adherence did 
influence non-attendance at the clinic.   This is contrary to the findings in the developing 
countries where better adherence was found to be independently associated with older age 
(>29 years) in both pregnant and non pregnant women (Rodriguez et al., 2007).     
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2.6 LOSS TO FOLLOW-UP  
 
With the rapid expansion of the Antiretroviral programmes, substantial rates of loss to 
follow-up in resource limited settings have been identified, however the causes of loss to 
follow-up in these settings have received little attention (Rosen et al., 2007; Dalal et al., 
2008). In a recent study, Dalal et al (2008) examined factors affecting retention in an urban 
public sector clinic in Johannesburg. Among 1631, 267 (16.4%) of the patients were 
classified as lost to follow-up with 65.9% being females.   
 
In a retrospective analysis of women referred to a community based clinic in Southern 
Africa, Kaplan et al (2008), found that although there was no significant difference in the 
mortality rates of pregnant and non-pregnant women, pregnant women had a substantially  
higher risk of loss to follow-up both pre-treatment and once treatment had started.   
 
Reasons for loss to follow-up were not established from Kaplan’s retrospective review, 
however loss to initiation (13.2% in pregnant vs. 6% in non pregnant women) and loss after 
initiation (32% pregnant on treatment vs. 13% non pregnant on treatment) were found to 
be substantially higher among pregnant women.  Those women that defaulted treatment 
were found to have done so within the first 3 months after initiation.  Pregnancy and age 
were independently associated with loss to follow-up (Kaplan et al., 2008).  In the pre-
treatment analysis, they found a crude overall programmatic loss of 19.8% among pregnant 
women as compared with 17.1% among non-pregnant women (p <0.243).  Pre-treatment 
mortality was significantly lower among pregnant women (0.3% vs. 4.7%; p<0.001) though 
the pre-treatment loss to follow-up was higher (13.3% vs. 6.0%; p<0.001). 
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The reason why pregnant women default treatment and become lost to follow-up is 
uncertain. However there is a possibility that some of patients being flagged as loss to 
follow-up may have transferred to another treatment facility, may have moved due to 
employment, or may have died (Bisson et al., 2008).  The administration of antiretroviral 
therapy to individual patients and the ongoing monitoring and evaluation of HIV/AIDS 
treatment programmes critically depend on regular and complete patient follow-up 
(Brinkhof  et al., 2008).  According to the systemic review by Rosen et al (2007), ART 
programmes in Africa have retained about 60% of their patients at the end of two years 
since the beginning of large scale ART access.  As per their findings, most patients in Africa 
initiate antiretroviral treatment only after an AIDS defining illness. In this review, loss to 
follow-up was found to be the main cause of attrition followed by death.   
 
2.7 MORTALITY 
 
Reducing maternal mortality, the fifth United Nations Millennium Development Goal, 
requires a thorough understanding of the causes of maternal death and of the contribution 
of avoidable or remediable factors.  The World Health Organization (WHO) estimates that, 
in 2005, there were 536, 000 maternal deaths worldwide.  
 
HIV has now become the single leading cause of death in South Africa, regardless of age, sex 
or race (Bradshaw and Dorrington ,2005; Pieterse et al., 2003; Dorrington et al., 2004). 
However, it is important to note that the burden of HIV disease is not distributed evenly 
across population groups in the country.  When the data are disaggregated by age, race and 
STUDENT No. 0611757A 
17 
 
sex, they demonstrate that black women (South African women of African descent) of 
reproductive age, as well as black children under five, are bearing the brunt of morbidity 
and mortality in South Africa due to HIV-related opportunistic infections.  Black South 
African women who are pregnant have the highest HIV prevalence in the country, estimated 
at 30.2% (Government of South Africa, 2007).  South African women in the 25 to 29 age 
group have an estimated HIV prevalence of 33%. 
 
According to the review by the National Committee on Confidential Enquiries into Maternal 
Deaths (NCCEMD) as outlined in the Saving Mothers 2005-2007 report, there has been a 
20.1% increase in the number of deaths reported compared with the previous triennium 
(2002-2004). The “big five” causes of maternal death have remained the same, namely non-
pregnancy related infections – mainly AIDS (43.7%), complications of hypertension (15.7%), 
obstetric haemorrhage (antepartum and postpartum haemorrhage; 12.4%), pregnancy 
related sepsis (9.0%) and pre-existing maternal disease (6.0%).  Women less than 20 years of 
age were at greater risk of dying due to complications of hypertension whereas women 35 
years and older were at greater risk of dying of obstetric haemorrhage, ectopic pregnancies, 
embolism, acute collapse and pre-existing medical disease. 
 
Non-attendance and delayed attendance at the health institutions were the most common 
patient orientated problems.  Poor transport facilities, lack of health care facilities and lack 
of appropriately trained staff were the major administrative problems. The most frequent 
health care provider avoidable factors were failure to follow standard protocols and poor 
problem recognition and initial assessment.  Assessors thought 38.4% of the deaths were 
clearly avoidable within the health care system (patient orientated factors being excluded). 
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Complications of hypertension, obstetric haemorrhage, pregnancy related sepsis and non-
pregnancy related infections were responsible for 4 out of 5 of avoidable deaths. 
 
Part of the challenge is likely owing to the difficulty in initiating HAART in a midwife-driven 
antenatal care service and the subsequent logical demands of coordinating HIV and 
antenatal care.   
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CHAPTER 3  METHODOLOGY 
 
3.1 INTRODUCTION 
 
In this chapter, the study design and methodology are presented.  The study population is 
described and selection of the study sample is explained.  The data collection system at the 
study site is described and details of the variables to be analysed are presented.  Definition 
of each clinical and immunological result as well as the outcomes of interest is given and the 
chapter ends with a review of the data analysis plan and ethical considerations of this 
project. 
 
3.2 STUDY DESIGN 
 
This study was an analytic retrospective cohort design using secondary data collected from 
all HIV positive women who initiated antiretroviral therapy from 1st January 2005 to 31st 
December 2007. Women were divided into three groups according to whether or not they 
were pregnant during the study period and the timing of any pregnancies in relation to the 
initiation of HAART. Adherence, loss to follow-up and mortality rates were the main 
outcomes compared between the groups.  
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3.3 STUDY SITE 
 
Themba Lethu Clinic is one of the largest public antiretroviral rollout sites in South Africa.  
The clinic is based at Helen Joseph Hospital and its population can be considered 
representative of an urban population accessing antiretroviral therapy in the public sector.  
Moreover, this clinic uses an electronic patient management tool in real time and, as such is 
one of the few sites with up-to-date longitudinal data available and accessible for secondary 
analysis. 
 
3.4 STUDY POPULATION 
 
The study sample consists of 5174 females initiated on HAART at the Themba Lethu Clinic 
between 1st January 2005 and 31st December 2007. Since January 2005, all pregnant women 
eligible for HAART were referred to Themba Lethu Clinic from the Coronation Women and 
Children Hospital.  All data from the patient’s records were completely captured onto an 
electronic data system by December 2007.  This allowed patients’ longitudinal information 
to be evaluated.  It is for this reason that the study period was chosen from 1st January 2005 
to 31st December 2007.  Of these 5174 women that enrolled, we had 4317 women who 
never had a pregnancy and 857 women that ever had a pregnancy during the study period.  
Although our original plan was to compare the differences between the pregnant and the 
non pregnant group, initial analysis revealed that the pregnant group of women could 
further be grouped based on the timing of the pregnancy.  Women who never had a 
pregnancy during the study period were termed as ‘not pregnant’ while women that were 
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pregnant at initiation were referred to as ‘pregnant at start’ and women who fell pregnant 
after initiation of HAART during the study period were referred to as pregnant after. The 
group of women that were pregnant at initiation and had a second pregnancy during the 
study period was too small for comparative analysis and so was excluded for simplicity.  
 
Exclusion criteria: 
 
 Female patients younger than 18 years of age at the time of enrolment in the clinic 
were excluded from the study. 
 Women who were not HAART naïve and who were transferred in from other 
treatment sites were excluded from the study as baseline clinical data for these 
women was not available and the study objective was to compare baseline 
characteristics with subsequent follow-up information in women based on 
pregnancy status. 
 
3.5 TRACING INTERVENTION 
 
The telephone tracing and home visit tracing was implemented in April 2007 for patients 
who had missed their scheduled appointments.  Three telephone call attempts at three 
different times and days are made to trace the patient. Traced patient are counselled and a 
new appointment is given.  Patients that cannot be contacted are referred to a team of 
community workers who do home visits to locate the patients by using the address 
provided. Those patients that cannot be found by the home visit team were confirmed lost 
to follow-up.   
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3.6 DEFINITIONS OF TERMS 
 
Right to Care 
 
Right to Care is a PEPFAR (President’s Emergency Plan for AIDS Relief) and USAID (United 
States Agency for International Development) funded NGO.  The NGO supports the ART 
implementation at the Themba Lethu Clinic in its development to build institutional capacity 
and establish organisational infrastructure required to support the implementation of the 
ART treatment programme. 
 
Antiretroviral therapy 
 
Anti-HIV drugs to suppress the progression of viral replication. 
 
Adherence  
 
ART Adherence was defined using the CD4 cell count response.  An increase in CD4 cell 
count from the baseline CD4 cell count by a rise of 100 cells or more after initiation of 
HAART denotes an effective immunological response.   
 
Adherence to ART suppresses the viral load.  Hence a decrease in HIV viral RNA to less than 
400 viral copies after initiating HAART denotes good virologic response due to adherence.  
Subsequent increases in CD4 cell count during the study also denotes good adherence with 
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an improvement in immunological response due to regular intake of prescribed HAART 
therapy. 
 
CD4+ T-lymphocyte count 
 
The number of "helper" CD4+ T-lymphocytes in a cubic millimeter of blood. With HIV, the 
absolute CD4 cell count declines as the infection progresses. The absolute CD4 cell count is 
frequently used to monitor the extent of immune suppression in persons with HIV.  
 
 
Viral Load 
 
 
Viral load means the level of virus found in the blood and is measured in the number of HIV 
RNA Copies/ml blood plasma. The viral load decreases with optimal treatment. The aim of 
the antiretroviral treatment is to have as low a viral load as possible i.e. an undetectable 
number of HIV RNA copies. The measuring method has become better over time and hence 
also the detection limit for viral load has decreased.  
 
Virological suppression 
 
Virological suppression was defined as a reduction of HIV viral load to less than 
400copies/ml. 
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Defaulter 
 
At the Themba Lethu Clinic, when a patient fails to return to the clinic one week after 
her/his scheduled ARV collection date, the patient is flagged as a defaulter. 
 
Loss to follow-up 
 
A patient is defined as lost to follow-up if she/he does not return to the clinic ≥3 months 
after the last scheduled medical or ARV collection visit date. 
 
Maternal Mortality 
 
Maternal mortality is defined as death of women while pregnant or within 42 days of 
termination of pregnancy from any cause related to or aggravated by the pregnancy or its 
management, but not from accidental or incidental causes. 
 
3.7 STUDY VARIABLES 
 
The exposure measured is pregnancy and the outcomes of interest are adherence, loss to 
follow-up and mortality.  ART adherence was measured using the CD4 cell count response 
and the HIV viral load suppression.  If a patient was not contactable after three telephonic 
attempts, the tracing was referred to the home base visit team.  Patients traced and not 
found by the home based team were confirmed as loss to follow-up. 
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3.8 DATA COLLECTION 
 
This study is based on secondary data analysis of the existing data collected by the Themba 
Lethu Clinic. The data are captured and stored at Themba Lethu clinic in a proprietary 
medical management system TherapyEdge – HIVTM.    Right to Care and the Clinical HIV 
Research Unit of the Department of Medicine at the University of Witwatersrand agreed to 
provide a de-identified dataset.   Any observation with values which seemed implausible 
were set to missing variables which were cleaned in this way included: 
 
Height – plausible values were deemed to be between 135 and 200 centimetres 
Weight - plausible values were deemed to be between 30 and 200 kilograms 
CD4 cell counts – these are reported as integers by the laboratory and so values with 
decimal places were considered typing or capturing errors and set to missing. 
 
TherapyEdge – HIVTM serves as a clinical Electronic Medical Records (EMR) solution and an 
HIV/AIDS disease management tool.  Longitudinal clinical data can be collected and 
reviewed to both evaluate treatment outcome and to identify trends in disease patterns.  
Patients’ demographic and contact details are recorded at the initiation visit.  At subsequent 
visits the patient’s vital signs, clinical notes, new diagnoses and medication profile is 
recorded in real time on the electronic patient management system.  Additionally, blood 
test results for CD4 cell count, HIV viral load, full blood count and liver function, which are 
done at each scheduled visit, are collected and entered onto the electronic database by 
trained data capturers. 
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3.9      DATA EXTRACTION  
 
The data was provided to the researcher from TherapyEdge – HIVTM after removing all 
personal identifying information. Baseline characteristics were obtained for the following: 
age, date of initiation, pregnancy status, WHO stage, CD4 cell count, viral load and 
employment status.  Data was also obtained for the following:  date of last ARV visit, date 
transferred out, date of death, and duration on treatment before becoming lost to follow-
up.   The analysis focused on female patients on HAART who met the inclusion criteria in the 
data set.   
 
3.10 DATA PROCESSING METHODS AND DATA ANALYSIS 
 
Data was analyzed using SAS v. 9.1.  The baseline characteristics of the three groups of 
women, pregnant at start, pregnant after and not pregnant were summarised using 
descriptive statistics.   Differences in demographic and clinical characteristics were 
compared between the three groups of women and associations of these characteristics 
with adherence and loss to follow-up were assessed using the Pearson chi-squared (X2) test 
for dichotomous variables.   ANOVA was used to compare the continuous outcome variables 
of the three groups.   
 
Loss to follow-up, duration on ARV treatment, CD4 cell count and viral load were used to 
define the key outcomes of interest.  These outcomes were compared between not 
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pregnant women, pregnant at start and pregnant after.  Potential confounders such as age 
and clinical stage were included in the analysis.  
 
Logistic regression was used to estimate the associations of baseline characteristics with 
adherence to estimate the odds of viral load suppression at 6 month intervals after HAART 
initiation for the three groups of women.  We first looked at the bivariate analysis of 
potential confounding variables before the multivariate analysis using Cox Regression 
models to estimate any association.  Only multivariate results are presented. 
 
Time to event analysis was performed using survival analysis techniques including Kaplan-
Meier estimates, a log rank test and proportional hazard model.  Survival analysis can be 
used to study any process where the outcome of interest is the time to the event.  In case of 
this study the outcome of interest is the time from initiation of HAART to being loss to 
follow-up.  Date of HAART initiation and date of final outcome were used as the start point 
and end point of follow-up time, respectively.  Survival analysis methods correctly use both 
censored and uncensored observations.  SAS v9.1 was used to compare survival 
distributions for the event-time variables of interest and to perform regression analysis 
based on the proportional hazards model to adjust for potential confounding variables.  All 
statistical significance was calculated using a 5% level of significance. 
 
3.11 ETHICAL CONSIDERATIONS 
 
Women in this study sample were identified by a unique identifier generated randomly by 
the TherapyEdge- HIVTM system.  The unique identifier does not relate to the participant’s 
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date of birth.  All personal identifiers were removed prior to the data being given to the 
researcher for secondary analysis.  The researcher was unable to identify participants in the 
sample or to collect informed consent from the same study population.  The study was 
conducted according to the Standard Operating Procedure (SOP) of the Clinical HIV 
Research Unit governing the analysis of data from the Themba Lethu Clinic Cohort (See 
Appendix A). Data was provided to the researcher only after obtaining permission from the 
clinic and hospital authorities.  
 
The study is a retrospective unlinked record review. The use of this retrospective data has 
already been passed (Blanket Approval) by the Human Research Ethics Committee (HREC), 
University of the Witwatersrand for use without informed consent (M060626) (APPENDIX 
A).   
 
Ethical clearance for this specific study was obtained from the HREC, University of the 
Witwatersrand (Protocol no. M080229) (APPENDIX B).  Permission to conduct the study 
(APPENDIX C) was also granted by the CEO of Helen Joseph Hospital where the Themba 
Lethu Clinic based. 
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CHAPTER 4  RESULTS 
 
4.1 INTRODUCTION 
 
This chapter presents the key results of the study.  We compare the baseline characteristics, 
adherence and loss to follow-up rates of three groups of women attending Themba Lethu 
Clinic.  Women who never had a pregnancy during the study period were termed as ‘not 
pregnant’ while women that were pregnant at initiation were referred to as ‘pregnant at 
start’ and women who fell pregnant after initiation of HAART during the study period were 
referred to as ‘pregnant after’.  We then tried to determine if the introduction of the tracing 
intervention made any difference in the proportion of pregnant women loss to follow-up. 
 
4.2 COHORT CHARACTERISTICS 
 
During the period from 1st January 2005 to 31st December 2007, 5584 women were enrolled 
on the antiretroviral treatment programme at the Themba Lethu Clinic.  Of these, 410 were 
excluded from the study as they were transferred into the clinic from other antiretroviral 
treatment programmes.   All women included in the study were treatment naïve at the time 
of initiation of HAART and older than 18 years of age.  The study sample consisted of 5174 
women.  857 (16.6 %) of the women were pregnant at some stage during the study period 
while 4317 (83.4%) women were not. In the pregnant group, 521 (60.7%) females were 
pregnant at initiation of antiretroviral treatment, 291 (33.9%) became pregnant while on 
antiretroviral treatment and 45 (5.2 %) women were pregnant at initiation and then had a 
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second pregnancy during the study period (Figure 1).  This group of women was too small 
for comparative analyses and therefore we excluded it from subsequent analyses.  The 
study sample that remained and was used in all the analysis consisted of 5129 women. 
 
Figure 1: Women Enrolled at Themba Lethu Clinic During the Study Period 
 
5174 (All women) 
 
4317 (Not pregnant)             857 (Pregnant) 
 
                                                521                    291                            45 
                                       (Pregnant at start)               (Pregnant after)               (More than one pregnancy) 
 
The enrolment of women at the Themba Lethu Clinic presented in Figure 2 shows that there 
has been a steady increase in the number of women enrolling at the clinic over the three 
years of the study period, 01 January 2005 to 31st December 2007.   However, the 
proportion of women pregnant at start is seen to have dropped in the 3rd year of the study 
period (43% in 2005, 43% in 2006 to 14% in 2007).  There was a gradual increase in the not 
pregnant group 29% in 2005, 35% in 2006 to 36% in 2007.  However, a gradual drop was 
also seen in the proportion of women pregnant after starting HAART over the study period 
from 45% in 2005, 34% in 2006 to 22% in 2007.   
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Figure 2:   Distribution of Women at Themba Lethu Clinic Over 3 Years 
 
 
 
4.3 BASELINE CHARACTERISTICS OF THE THREE GROUPS OF WOMEN  
 
The women pregnant at start were significantly younger with a mean age at initiation of 
(29.8 years, SD=5.06) compared to the not pregnant women with a mean age at initiation 
(36.2 years, SD = 8.53).  There was no significant difference in the mean age (30.2 years, 
SD=4.93) of women pregnant at start compared to women pregnant after.    
 
Multiple comparison of baseline CD4 cell count using Bonferroni test showed that the CD4 
cell count between women pregnant at start was significantly higher than the baseline CD4 
cell count of the not pregnant group (F=38.44, p=0.0001) and the women pregnant after 
HAART initiation, while there was no significant difference in the baseline CD4 cell count of 
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the not pregnant and the women pregnant after HAART (F=7.43, p=0.0856).   Pregnant 
women had the highest average BMI of 27.1 due to the added weight of the unborn baby. 
However, there was no significant difference in the BMI among the women pregnant after 
(F=1.10, p=0.3346) and the not pregnant women.   
 
There is a significant difference (X2 =181.7 p=<0.001) in the baseline WHO stage among the 
three groups of women.  Three quarters of the women pregnant at start presented with 
WHO stage one, while 43.2% of the women pregnant after HAART initiation and 39.7% of 
the not pregnant women, presented with WHO stage one.   On the other hand, just over 1% 
women pregnant at start reported with WHO stage four compared to almost 10% not 
pregnant women presenting with WHO stage four.  
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Table 1:  Baseline Characteristics at Initiation of HAART by Pregnancy Status 
 
  Not-pregnant            Pregnant at start  Pregnant after   Statistical  Test 
Total    (n)  4317  521  291 
 
Age (years)  (mean, SD) 
(n=4317) 
36.2 years (8.5) 
(n=521) 
29.8years (5.0) 
(n=291) 
30.2years (4.9) 
F = 202.81 
(p=<0.001)† 
Employment status                                             
employed %                                                              
unemployed   % 
(n=4317)                
38.04%                 
61.98% 
(n=521)                         
36.2%                     
63.7%  
(n=291)                   
32.1%                     
67.6%  
X
2 =4.21  
(p=0.122)‡ 
Year of initiation (n, %)                          
2005                                                  
2006                                                 
2007 
(n=4317)                         
28.8%                                         
34.7%                                       
36.4% 
(n=5210)                  
43.1%                                 
43.1%                                    
13.6% 
(n=2910)                     
44.6%                                 
33.6%                                    
21.6% 
 X
2 =143,3 
(p=<0.001)‡ 
Baseline CD4 cell count 
(cells/mm
3
)  (mean, SD) 
(n=3734)                             
110.89cells/µL  
(SD=111.09) 
(n=425)                            
149.33cell/µL 
(SD=76.50) 
(n=260)                  
118.32cells/µL 
(SD=115.19) 
F =24.0       
(p=0.001) † 
Baseline BMI (kg/m
2
)                    
(mean, SD) 
(n=3311)                                                        
23.8 (SD=5.3) 
(n=399)                                    
27.1 (SD=5.0) 
(n=231)                                   
22.6 (SD=5.2) 
F
 
=1.10  
(p=0.3346)† 
Baseline WHO 
I 
(n=2942)                     
43.2% 
(n=430)                       
75.1% 
(n=214)                    
39.7%   
II 14.1% 13.0%  16.3% 
X
2 =181.7 
(p=<0.001)‡ 
III  31.4%  10.70% 35.5%   
IV  11.2% 1.16%  8.8%   
Baseline TB (n)  % 
No 
Yes 
 (n=4317)                  
86.0%                    
13.94% 
(n=521)                      
96.35%                    
3.65% 
 (n=291)            
81.44%                   
18.56% 
X
2 =51.0 
(p=<0.001)‡ 
Baseline Hb g/dL                         
(mean, SD) 
(n=3732)                                               
11.1 g/dL (4.0) 
(n=294)                                 
11.2 g/dL (4.0) 
(n=254)                                    
11.0 g/dL (2.2) 
F =0.20  (p=0.8177) 
† 
†  ANOVA  
   ‡ Pearson's Chi-square 
*Kruskal-Wallis 
   
 
There was significant difference among the three groups of women regarding the 
presentation of tuberculosis at baseline (X2 =51.0; p=<0.001). Women who were pregnant 
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at start had less advanced disease compared to the not pregnant women and women 
pregnant after. 
 
Table 2 shows the distribution of the CD4 cell count category per pregnancy status at 
baseline.   This confirms that these women had already a much compromised immune 
system prior to starting HAART.  The overall CD4 cell count at initiation of HAART for this 
cohort was 126.1 cell/mm3 which is significantly lower than the cut off CD4 of 200 cell/mm3 
according to the National Treatment Guideline.   
 
Table 2 below shows that there was not much difference in the presentation of baseline 
CD4 cell count between the not pregnant women and the women pregnant after HAART.  
 
Table 2:   Distribution of Baseline CD4 Category Based by Pregnancy Status 
 
 
However, there is a significant difference in the presentation of baseline CD4 cell count of 
women pregnant at start,  the not pregnant women and the women pregnant after (X2 
=140.1;  p=0.001).  Of the women pregnant at start 50% presented with CD4 cell count 
Baseline CD4 Not pregnant n=3734 Pregnant at start  n=425 Pregnant after  n=260 
<50 1258 (33.6%) 42 (9.8%) 76 (29.3%) 
50-100 750 (20.0%)  71 (16.7%) 54 (20.7%) 
100-200 1257 (33.6%)               213(50.1) 99 (38.0%) 
>200 469 (12.5%) 99 (23.2%) 31 (11.9%) 
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between 100-200cells/ mm3 while only 33.6% not pregnant women and 38.0% women 
pregnant after HAART presented with a baseline CD4 cell count between 100-200cell/ mm3.  
 
4.4 ADHERENCE  
 
Two time periods were considered – CD4 cell count response 6 months after initiation of 
HAART and at 12 months after initiation of HAART.     
 
4.4.1 CD4 cell count response  
 
Only 2279/5128 women (44.4% of the cohort included in this analysis) had a CD4 cell 
recorded at 6 months after HAART initiation.  The question of interest was whether there 
was any difference in CD4 cell count responses between the three groups of women based 
on pregnancy status.      
 
4.4.2 CD4 cell count response at six months after HAART initiation 
 
The mean overall CD4 cell count response at 6 months was 262cell/mm3.  We looked at >50 
cell/mm3 CD4 response at 6 months and >100 cell/mm3 CD4 cell count response at 12 
months and the differences between the three groups of women based on pregnancy status 
are presented in Table 3.  
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Figure 3: Mean CD4 at 6 Month Intervals after Initiation of HAART 
 
 
 
Women pregnant before initiation of HAART had higher baseline CD4 cell count compared 
to women pregnant after HAART initiation and not pregnant women and this difference 
between the mean CD4 cell count at 6 months and 12 months after initiation increased even 
further.  This is shown in Figure 3 above.  This progressive increase in CD4 cell count is 
purely attributed to the baseline immunological status of the women pregnant at start. 
 
Table 3 below shows the percentage of women having a CD4 cell count response at 6 
months and 12 months in the three different groups based on their pregnancy status.  
Pregnancy status had no significant advantage in terms of CD4 cell count response. 
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4.4.3 Bivariate and multivariate analyses of factors associated with CD4 cell count 
response 
 
We did the bivariate analysis (results not shown) and confirmed by multivariate logistic 
regression (Table 4) of the factors associated with evidence of adherence at 6 months.  
Pregnancy status did not influence a positive CD4 cell count response at six months. 
However, women pregnant at start were more likely to achieve a 100 cell increase in CD4 
cell count both at six months and twelve months after HAART initiation.  These odds were 
adjusted for age and baseline CD4 cell count.  Both age at initiation and baseline CD4 cell 
count were found to have an independent association to response at six months in 
multivariate analysis.  
 
 
 
 
Table 3:  CD4 Cell Count Response 6 and 12 Months after Initiation of HAART by   
                Pregnancy Status 
 
 
Not-pregnant Pregnant at start Pregnant after X2  , P value 
Overall   (n)    
5128(100%) 
4317  520 291 
 
CD4  Response at 6 
months                                
1919 /2412 179 / 216 181 /220 
X
2 
=2.1 (p=0.347) 
(80%) (83%) (82%) 
CD4 Response at 12 
months 
1453 / 1958 133 / 164 129 / 179 
X
2
=4.4 (p=0.111) 
(74%) (81%) (72%) 
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Table 4:   Factors Associated with CD4  Cell Count Response at 6 Months after  HAART    
                Initiation  
 
Factors  
Multivariate Models                                                                              
Odds Ratio         (CI)             p-value 
Pregnancy                      
 
1                                                                                                                        
0.771      (0.476 - 1.250)     0.2917                                       
0.704      (0.428 - 1.161)     0.1692 
Not Pregnant                                                
Pregnant  at start                                                                  
Pregnant after  
Age at initiation 1.018       (1.003 - 1.032)      0.0185 
Baseline CD4  1.004       (1.002 - 1.005)     <0.001 
Baseline BMI 0.995        (0.973 - 1.018)     0.6740 
Employment Status                                
Employed                                               
Unemployed   1.173       (0.922 - 1.492)     0.1934 
Baseline TB 1.027       (0.705 - 1.497)     0.8887 
 
 
4.4.4 Virological Response 
 
2579 participants had HIV RNA viral load records for analysis.  Of these 83.9% (n=2163) not 
pregnant had a mean viral load of 17193.2, 8.4% (n=219), women pregnant at start had a 
mean viral load of 1466.9, 7.6%  (n=197) women pregnant after HAART initiation had a viral 
load of 7969.7.   
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Table 5:  Virological Suppression 6 and 12 Months after Initiation of HAART by  
               Pregnancy Status 
  Not-pregnant Pregnant at start Pregnant after   P value 
Overall   (n)    5128(100%) 4317 520 291 
  
Virological response at 6 
months n (%)               
2163(50%)      219(42%) 197(68%) 
X
2 
=1.31 
p=0.2701 
Virological response at 12 
months n (%)                  
1457(34%) 157(30%) 152(52%) 
X
2 
= 0.94            
p=0.3892 
 
 
There were no significant differences in the proportion in the three groups of women 
achieving virologic suppression at six months (X2 =0.1.31, p=0.2701) and twelve months (X2 
=0.94, p=0.3892) after initiating HAART.    
 
4.4.5 HIV viral load suppression at six months after HAART initiation 
 
Factors associated with suppression of HIV viral load at 6 months after initiation of HAART 
were investigated using a logistic regression model.    Bivariate analysis was done first to 
check the association with possible confounders. Multivariate results are presented in Table 
6.  
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Table 6:  Factors Associated with HIV Viral Load Suppression 6 Months after  HAART Initiation  
 
Factors  
Multivariate Model                                                                     
Odds Ratio                   (CI)                     p-value 
Pregnancy                       
1                                                                                                          
1.225                (0.602 - 2.493)             0.575                               
1.150                (0.620 - 2.134)             0.656 
Not Pregnant                               
Pregnant  at start          
Pregnant after HAART 
Age at initiation 1.006               (0.986 - 1.027)             0.520 
Baseline CD4 1.000               (0.998 - 1.003)            0.351 
Baseline BMI 1.013               (0.979 -1.049)             0.445 
Employment Status    Employed                
Unemployed 1.332                (0.938 - 1.892)          0.109 
Baseline TB 0.926              (0.553 - 1.550)            0.770 
Baseline                              
 WHO1                                           
WHO2                                              
WHO3                                          
WHO4 
1                                                                                                           
0.764           (0.474 - 1.229)            0.268                                    
1.001           (90.643 - 1.559)          0.993                                   
1.019           (0.545 - 1.906)            0.951 
 
 
After complete adjustment, women pregnant at start and women pregnant after HAART did 
not have significantly different odds of suppression compared to not pregnant women at 6 
months (p=0.2701).  In bivariate analysis, baseline CD4 cell count (p=0.030) and 
employment status (p=0.003) showed evidence of association to virolgic suppression. After 
adjusting for CD4 cell count and employment status in the multivariate anslysis there was a 
no influence of employment status or baseline CD4 cell count by pregnancy status to 
virological suppression.  None of the coviariates significantly predicted virologic suppression 
at 6 months after initiation of HAART in bivariate analysis and multivariate analysis. 
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4.5 OUTCOMES OF WOMEN ON HAART BASED ON PREGNANCY STATUS 
 
4.5.1 Loss to follow-up 
 
Of the 5129 women in this cohort, 1318 (25.6%) women were loss to follow-up by the end 
of the study period (31st December 2007).   Analysis based on pregnancy status revealed 
that 1042 (24.1%) not pregnant and 276 (33.9%) pregnant women were lost to follow-up.  
215 (41.2%) women pregnant at start and 57(19.5 %) of women pregnant after were loss to 
follow-up at 3 months after HAART initiation.  Analyses of loss to follow-up at 6 months 
showed that 204 (39.1%) women pregnant at start, 23 (7.9%) women pregnant after and 
949 (22.0%) not pregnant women were lost to follow-up.   
 
4.5.2 Loss to follow-up 3 months after initiation of HAART  
 
The proportion of women lost to follow-up is significantly higher in women pregnant at start 
(X2 =115.3, p= <.0001) compared to not pregnant women and women pregnant after.  Risk 
factors for loss to follow-up were estimated and.  Odds ratio for variable were calculated and 
presented in Table7.  There is evidence of a difference in odds of becoming loss to follow-up 
between women pregnant before and women pregnant after HAART initiation.  Age at 
initiation, baseline CD4 cell count and employment status showed significant association 
with odds of becoming loss to follow-up in both bivariate and multivariate analysis.  
Multivariate results are presented in Table 7. 
 
 
STUDENT No. 0611757A 
42 
 
Table 7:  Factors Associated with Loss to Follow-up 3 Months after Initiation 
 
Factors  
 
Multivariate Model                                                           
Odds Ratio                  (CI)                   p-value 
Pregnancy Status                                
 Not pregnant                                     
Pregnant at start                     
 Pregnant After  
 
1 
1.824            (1.540  -  2.161       <.0001                                         
0.295            (0.199 - 0.437)       <.0001 
Age at initiation 0.992            (0.984 - 0.999)          0.050 
Baseline CD4 0.998          (0.998 - 0.999)          <.0001 
Employed                                 
Unemployed 
1                                                                                          
0.686          (0.603 - 0.780)          <.0001 
Baseline TB 0.826          (0.640 - 1.066)         0.142 
Baseline BMI 0.996               (0.981 - 1.010)         0.584 
 
 
4.5.3 Loss to follow-up 6 months after initiation of HAART 
 
Women, who became pregnant after initiation of HAART, seemed two times less likely of 
becoming loss to follow-up in bivariate analysis and three times less likely in multivariate 
analysis when compared to the women who were pregnant before HAART initiation.  An 
apparent association between being pregnant and the odds of becoming loss to follow-up is 
observed multivariate analyses.   
 
STUDENT No. 0611757A 
43 
 
4.5.4 Time to loss to follow-up 
 
During the study period, 3879 women that remained in the study contributed a mean of 2.1 
years of observation for analysis compared to 1286 women that became loss to follow-up, 
contributed a mean of 1.01 years of observation in the analysis.  Differences in the rate of 
loss to follow-up were estimated using Kaplan-Meier (KM) survival curves (figure 4) and 
incidence rates expressed in person-years.   
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Figure 4:  Kaplan-Meier Plots for Loss to Follow-up for Women at Themba Lethu Clinic 
 
Kaplan-Meier survival estimates 
 
 
 
 
 
 
 
 
 
Figure 4 shows the loss to follow-up rate in all three categories of women.  The highest rate 
of loss to follow-up is seen in the women pregnant at start (41.2%) at 3 months followed by 
not pregnant women (24.1%).  Women pregnant after had the lowest rate of loss to follow-
Pregnancy 
Status 
Time at 
risk 
Incidence 
rate 
No. of 
subjects 
events 
observed 
Not pregnant 2930292 <0.001 4309 1042 
Pregnant at 
start 345218 <0.001 521 215 
Pregnant after 278260 <0.001 291 29 
     X2=115.32, p=<0.001 
   
Not pregnant=0;   Pregnant after =1; Pregnant at start=2 
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up (9.94%). This trend was consistent for loss to follow-up at 3 months and loss to follow-up 
at 6 months after initiation. 
 
As seen in Table 8, proportional hazard of showed that women pregnant at start were 11.9 
times more likely to become loss to follow-up followed by women pregnant after who were 
6.68 times more likely to become loss to follow-up when compared to not pregnant women.  
Being pregnant shows a significant hazard for becoming loss to follow-up. 
 
Table 8: Hazard Ratio for Being Loss to Follow-up Based on Pregnancy Status 
 
 
    Hazard Ratio      95%HR confidence          X2                                     p value 
Not pregnant 1 
 
Pregnant at start 0.851                    (0.777 -  0.933) 11.9                    <0.0001 
Post pregnant 1.170                    (1.039  -  1.318)  6.68                    <0.0001 
 
 
4.6 MORTALITY  
 
There were 5129/5174 women for survival analysis as we had excluded the 45 women who 
had a pregnancy at start and a second pregnancy later during the study. 246 deaths (4.79% 
of the total cohort) were recorded before the final date of 31st December 2007.  Of those 
who died, 234/246 (95.1%) were not pregnant women, 9/246 (3.6%) women pregnant at 
start and 3/246 (1.2%) women pregnant after initiating HAART.  The Chi-square test showed 
that the proportion of not pregnant women who died was significantly greater than the 
proportion of the women who died in both the pregnant groups (X2=23.92 p=<.0001). 
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We further analyzed the alive traced women (n=240) with those deceased and those that 
could not be found after tracing.  Compared to those women who were traced living, those 
who died were found to be significantly older at initiation (37.6 vs. 35.0 years; P=0.0015), 
had a much lower CD4 result at initiation (65.7cell/mm3 vs. 118 .7cell/mm3; P=<.0001).  
Furthermore, 52 (20.9%) of those that died (n=248, 19.1%), had tuberculosis at initiation.  
Both women pregnant women at start and women pregnant after were significantly 
younger at initiation of HAART and had less-advanced HIV disease than the not pregnant 
women initiating HAART.   
 
Figure 5:  Kaplan-Meier Plot s for Death for Women at Themba Lethu Clinic by Pregnancy  
                Status 
 
 
  
Kaplan-Meier survival estimates 
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These women contributed a mean of 1.85 person years of observation for analysis during 
which 246 failure events (deaths) occurred.   Rate of death among the three groups of 
women was estimated using Kaplan-Meier (KM) survival curves and incidence rates 
expressed per person-days.  The log-rank test for equality of survivor functions showed that 
the time to death for not pregnant women was significantly greater than the women 
pregnant at start and women pregnant after (X2=23.92, p=<0.001).   
 
 
 
 
 
 
 
 
 
 
 
Pregnancy 
Status 
Time at 
risk 
Incidence 
rate 
No. of 
subjects 
events 
observed 
Not pregnant 2930292 <0.001 4309 234 
Pregnant at 
start 345218 <0.001 521 9 
Pregnant after 278260 <0.001 291 3 
     X2=23.92, p=<0.001 
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4.6.1 Factors associated with mortality after HAART initiation 
 
Risk factors for mortality after initiation of HAART were estimated using Cox logistic 
regression model.  Odds ratio for each variable was first calculated for bivariate and then 
the multivariate results were calculated.  The multivariate results are presented in Table 9. 
In the bivariate analysis, women who became pregnant after HAART initiation were five 
times more protective to death after HAART initiation and women pregnant at start were 
three times more protective to death after HAART initiation when compared to not 
pregnant women. 
 
Table 9:  Factors Associated with Death after  HAART  Initiation  
   
Factors  
Multivariate Model          
 Odds Ratio                  (CI)                     p-value 
Pregnancy                                                              
Not  Pregnant                                             
Pregnant  at start                            
Pregnant after  
1                                                                                                    
 1.534                (0.649-3.621)            0.3294       
5.067               (1.236-20.772)           0.0242 
Age at initiation  0.972               (0.955-0.990)            0.0022 
Baseline CD4  1.008              (1.00 -1.011)              <.0001 
Baseline BMI 1.015              (0.983-1.047)             0.3624 
Employment Status    
Employed                
Unemployed 1.190              (0.849-1.669)           0.3128 
Baseline TB 0.637            (0.430-0.943)            0.0243 
Baseline                              
WHO I                                      
WHO II                                     
WHO III                                        
WHO IV 
1                                                                                      
1.528                 (0.896-2.607)         0.119                 
1.421                 (0.894-2.258)         0.137              
1.677                 (0.953-2.949)         0.072 
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Other strong significant predictors of death in the bivariate analysis included baseline CD4 
cell count and baseline WHO stage, and a weak association of age at initiation and 
employment status. 
 
4.7 OUTCOMES BEFORE AND AFTER TRACING INTERVENTION 
 
As the tracing intervention was implemented in April 2007, we looked at the experience of 
the three groups of women before the 31st March 2007 and their experience after. The 
period from 1st January 2005 until the 31st March 2007 was considered as period 1 and the 
time period from 1st April 2007 to 31st December 2007 was considered period 2.  Not every 
woman in the study was at risk to become loss to follow-up in the two time periods. Those 
women that initiated treatment before 31st March 2007 were at risk in period 1.  While 
women that initiated treatment after 31st March 2007 were at risk in period 2. However 
there may have been women who span 31st March 2007 from period 1.  
 
In the survival analyses (Figure 6), we do not see any significant difference in the loss to 
follow-up rate before and after the intervention [HR=1.003 [95%CI (0.888-1.133)]; 
p=0.9509].  The reason for this is the time period between the introduction of the tracing 
intervention and the end of the study was only 9 months.  This period is not long enough to 
evaluate the intervention.  Moreover, it is important to understand that not all women that 
initiated treatment after 31st March 2007 did so at the same time.  Hence there may have 
been women who initiated treatment very close to the end of the study period.  Therefore 
there was not enough time to measure the outcome of the intervention.   
 
STUDENT No. 0611757A 
50 
 
Figure 6:  Kaplan-Meier Plot for Lost to Follow-up before and After Active Tracing 
 
 
HR=1.003 [95%CI (0.888-1.133)]; p=0.9509 
 
Of the overall 1295 (25%) patients loss to follow-up, a total of 517 (39.9%) were unable to 
be traced due to incorrect contact details while 240 (18.5%) were successfully traced.  Those 
that could be contacted provided clearer statistics and were further categorized based on 
the outcome of tracing.  That is: - confirmed loss to follow-up, transferred out to another 
treatment facility, dead, and those that were traced were encouraged to return to the clinic.  
 
4.7.1 Analysis of outcomes before and after patient tracing 
 
Table 10a and Table 10b presents the outcomes before and after the implementation of the 
tracing intervention respectively.  Prior to the tracing intervention, a total of 1318 (25.6%) 
0.00 
0.25 
0.50 
0.75 
1.00 
0 500 1000 1500 
Analysis time 
Before tracing  After tracing  
Kaplan-Meier survival estimates 
STUDENT No. 0611757A 
51 
 
women who initiated treatment between January 2005 and December 2007 were identified 
to be lost to follow-up. Out of these women, those that were pregnant and loss to follow-up 
accounted for 276 (33.9%).   Further analysis (Table 10a) revealed that women pregnant at 
start shows almost double the rate of loss to follow-up compared to the not pregnant 
women and women pregnant after initiating HAART.  
 
Table 10a:  Loss to Follow-up before Tracing Intervention  
 
 
 
 
 
 
 
 
 
 
Table 10b:  Outcomes after Tracing Intervention 
 
 
 
 
               LTFU before tracing intervention 
 Status 
Not pregnant 
(n=4317) 
Pregnant at 
start 
(n=521) 
Pregnant after     
(n=291) 
 
Total                   
(n=5129) 
Lost Before 
tracing 1042 (24.1%) 219(41.2%) 57 (19.5%) 
 
 
1318 (25.6%) 
                 Outcomes of the women loss to follow-up after tracing intervention 
 
Total  LFT-up                 
 
 
Dead   
 
 
Confirmed LTFup    
 
 
Transferred out 
 
 
 
Traced      
 
Not pregnant 
(n=1042) 236(22.6%)  377(36.1%) 267(25.6%) 
 
 
162(15.5%) 
Pregnant at 
start (n=219) 9(4.1%) 130(59.3%) 36(16.4%) 
 
 
44(20.0%) 
Pregnant after  
 (n=57) 3(5.2%) 10(17.5) 12(21.0%)  
 
 
32(56.1%) 
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The tracing intervention helped to identify the true outcomes of the 1318 (25.6%) women 
initially flagged as loss to follow-up (Table 10b).  Women pregnant at start of HAART showed 
the highest rate of confirmed loss to follow-up compared to the not pregnant group and the 
women pregnant after initiating HAART.  Of all the women confirmed to be loss to follow-
up, 140 (27.0%) were pregnant women. 
 
Among all the women that were loss to follow-up, tracing revealed that death was much 
higher in the not pregnant group 236 (22.6%).  In this study cohort (5129), mortality was 
significantly lower among pregnant women compared to the not pregnant group (1.4% vs. 
5.4%; P =<0.001).  Among the pregnant group, mortality was significantly higher in the 
women pregnant at start (1.7 % vs. 1.0 %; P= <0.001) compared to the women pregnant 
after.   
 
4.8       OVERALL RETENTION AFTER TRACING INTERVENTION 
 
Combining all losses in the cohort, i.e. death, loss to follow-up and transferred out to 
another treatment model, the overall retention of the cohort after the tracing intervention, 
we found being pregnant at start and pregnant after HAART, baseline CD4 cell count and 
employment were significantly associated with overall retention (Table 11).  Bivariate 
analyses (results not shown) were done first before the multivariate analyses.  The hazard 
for lost to follow-up was significantly associated with being pregnant.  Results in Table 11 
confirm that there is also a strong association with being unemployed and becoming lost to 
follow-up.   
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Table 12 summarises the factors associated with the key outcomes of this study.  We find 
that age at initiation (p=0.0185), baseline CD4 cell count (p=<0,001), are significantly 
associated with adherence and CD4 cell count response.  However, no variables showed any 
association with virologic suppression.   
 
 
 
 
 
Table 11: Factors Associated with Overall Retention after Active Tracing  
                  Intervention 
 
  
Factors  
Multivariate Model                  
Hazard Ratio                       (CI)                        p-value 
        
Pregnancy 
 
Not Pregnant                                              
 
Pregnant  before HAART                             
 
Pregnant after HAART 
 
 
 
1 
 
1.909                  (1.529 -  2.383)                 <0.001 
                                                                                                    
 0.298                   (0.183  - 0.486)                <0.001 
 
Age at initiation 0.992                (0.983  -  1.002)                  0.145 
Baseline CD4 0.998               (0.997  -  0.999)                 0.020 
Baseline BMI 0.996                (0.981  -  1.010)                 0.586 
Employment Status                         
Employed                                         
Unemployed 
1                                                                             
 0.656             (0.556    -  0.774)                <0.001 
Baseline WHO                                       
WHO  I                                                       
WHO II                                                      
WHO III                                                    
WHO IV 
1                                                                            
 0.935                 (0.746  -  1.173)               0.564      
 0.901                 (0.733  -  1.107)              0.322       
1.046                  (0.827  -  1.180)              0.897 
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Table 12:  Summary of Factors Related to Outcomes of Interest  
 
Outcomes 
Significant Factors 
Multivariate Model                  
            Hazard Ratio         (CI)              p-value 
Adherence  
(CD4 cell count response) 
Age at initiation            1.018          1.003-1.032      0.0185 
Baseline CD4                  1.004          1.002-1.005      <0,001 
Viral suppression None of the covariates significantly predicted virologic suppression 
Loss to follow-up Pregnant at Start             1.824       1.540-2.161        <.0001                                      
Pregnant After                 0.295        0.199-0.437       <.0001 
Age at initiation               0.992       0.984-0.999        0.050 
Baseline CD4                    0.998         0.998-0.999     <.0001 
Unemployed                    0.686         0.603-0.780      <.0001 
Mortality Age at initiation               0.972        0.955-0.990       0.0022 
Baseline CD4                     1.008         1.00 -1.011       <0.0001 
Baseline TB                       0.637         0.430-0.943       0.0243 
 
 
Pregnancy is found to be strongly associated with becoming loss to follow-up.   Age at 
initiation and being unemployed are also found to be significantly associated in becoming 
loss to follow-up.  In the case of mortality, age at initiation, baseline CD4 and having 
tuberculosis at baseline are strongly associated with mortality. 
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CHAPTER 5  DISCUSSION 
 
The aim of this study was to determine and describe differences in adherence and loss to 
follow-up in a population of HIV infected women at the Themba Lethu Clinic.  Our original 
plan was to compare the baseline and outcome characteristics between pregnant and non 
pregnant women.  However, our initial analyses revealed that we needed to further divide 
our pregnant group of women based on the timing of their pregnancy.  We found that 
women who started treatment because they were pregnant had significant differences in 
their baseline and outcome characteristics compared to the women who later became 
pregnant after starting HAART and women who were never pregnant during the study 
period. 
 
The results show that there was no difference in the immunological and virological response 
among the three groups of women based on pregnancy status.  However, the risk of loss to 
follow-up was much greater in pregnant women compared to not pregnant women.   
 
To our knowledge this is the only study that has tried to identify the association of 
pregnancy with adherence and loss to follow-up in HIV positive women in sub-Saharan 
Africa.  
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5.1 BASELINE CHARACTERISTICS 
 
In our study we found age at initiation was significantly associated with immunological 
response.  Older women have been described to show significantly better adherence in 
majority of other studies measuring adherence in this population (Bardeguez et al., 2008; 
Laine et al., 2000; Vaz et al., 2007; Nachega et al., 2007).  Taking medication regularly can be 
overwhelming for younger individuals.  Older women may have the maturity and stability in 
accepting the disease than the younger women.  Moreover younger women may face 
challenges of disclosing to their partners due to fear of rejection, and may not have the 
social support and this may have an impact on adherence patterns and regular clinic visits.  
These women may have lacked the maturity to accept this chronic illness requiring life-long 
commitment to adherence.  Moreover, these women may not have the knowledge of 
serostatus prior to conception; are reluctance to test in pregnancy; have fear of disclosure 
and denial post diagnosis, unaware of the importance of regular clinic visits and the 
understanding of the consequences of poor adherence (Volmink J et al., 2007).   This 
demands a need to target teenagers for education interventions before they become 
sexually active.   Baseline CD4 cell count is also found to be significantly associated with 
adherence and a positive response in CD4ce count.  Accessing antiretroviral therapy with an 
already compromised immune system is also significantly associated with having poor CD4 
cell response. 
 
There is a steady increase in the overall enrolment of women at Themba Lethu clinic over 
the study period however, the distribution of women based on pregnancy status in this 
cohort is changing over time. The first two years of the study we found a consistent number 
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of women pregnant at start of HAART enrolling at the clinic, however in the third year this 
dropped substantially.  Pregnancy after initiating HAART also seems to have dropped over 
the three year study period.  This drop in the number of pregnant women enrolling on the 
ARV treatment program is of concern.  Women referred from antenatal care services may 
never access HIV services or may prolong access until they are too ill.  Most pregnant 
women attending the antenatal care at Coronation Women and Children Hospital learn their 
HIV status for the first time.  These women are referred to Themba Lethu clinic for HIV 
management and care.  One of the concerns raised from the drop seen in pregnant women 
enrolling in the third year may be attributed to loss to initiation. This is a growing concern of 
treatment denial.  Pregnant women accessing HIV treatment late in their pregnancy may 
not have immediate benefits from the antiretroviral treatment which may increase the risk 
of vertical transmission.  An overwhelming majority (90%) of HIV infected children acquire 
the infection through mother-to-child transmission (UNICEF, 2008; WHO 2008).  Also 
according to the National Committee on Confidential Enquiries into Maternal Deaths 
(NCCEMD), HIV AIDS accounts for 43.7% maternal deaths.  This further affirms that  
pregnancy is related to being loss to follow-up.    
 
The psychosocial impact in women with HIV infection on pregnancy has been documented 
in women with both pre-conception and post-conception HIV diagnosis, and anxiety during 
pregnancy is commonly associated with disease-related stigma and fear of risk of vertical 
transmission (Bwirire et al., 2008; Creek et al., 2007; Bardeguez et al., 2008).  
 
Another important reason for fewer pregnant women accessing the treatment programme 
may be financial constraints. Transport cost being a barrier for regular clinic visits has been 
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reported for the general population in a study in this setting (Maskew et al., 2006). The 
services and treatment at the Themba Lethu Clinic is offered free of charge but patients still 
need transport money to get to the clinic, which is often far from their homes or place of 
work.  Additionally, unemployment is significantly associated with being loss to follow-up in 
both bivariate and multivariate analysis.  Pregnant women are required to have an 
antenatal visit at the antenatal clinic and an ARV visit at the ARV clinic on a monthly basis.  
These women are probably having difficulties getting time off work for regular clinic visits or 
loss of income due to days of work missed may prevent them from accessing treatment.   A 
visit to the clinic often involves a significant part of the day spent in queues.  
 
This highlights the need to have integration of our antenatal and ARV services at primary 
health care level in order to provide comprehensive services at one clinic.  Dispensing more 
than one month’s supply to stable patients is another option to reduce the number of visits. 
 Integration of antenatal services, along with TB and HIV treatment services may maximize 
the effectiveness of interventions aimed at patient retention and reduction in morbidity and 
mortality.   
 
5.2 ADHERENCE  
 
Women pregnant at start of HAART had a higher baseline CD4 cell count compared to the 
not pregnant women and the women pregnant after starting HAART, however there was no 
significant difference in CD4 cell count response and virological suppression in the three 
groups of women based on their pregnancy status at six months and twelve months after 
HAART initiation.   
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Data from previous studies have identified adherence as a strong predictor of virological 
outcomes and survival in people with HIV infection (Nachega et al., 2006; Nachega et al., 
2007; Paterson et al., 2000).  Our data is consistent with this conclusion, however pregnancy 
did not influence clinical outcomes in our study.  We did not find any significant difference 
in virological suppression in the three groups of women based on their pregnancy status.   
 
Studies from the developed world looked at adherence based on pharmacy claims.  These 
studies showed contrasting results.  Several studies of women in the United States 
evaluating adherence with self-reporting and pill count levels found that adherence rates to 
HAART were highest among pregnant women compared to non pregnant women (Vaz et al., 
2007; Zorilla et al., 2003).  This could be due to monthly medical appointments that are 
required during the antenatal period, giving an opportunity to motivate pregnant women to 
adhere to their ARV treatment (Vaz et al., 2007).  However, results from a study using 
pharmacy claim adherence in a larger cohort of American women showed that observed 
rates in pregnant women were generally poorer than the rates reported by non pregnant 
women (Laine et al., 2000).  Potential obstacles identified were the added emotional and 
physical stress that pregnant women may experience, such as nausea, worries about the 
complex dosing schedule of HAART (Laine et al., 2000).  Since our study was a retrospective 
review, we were unable to determine such predictors of adherence. 
 
We further examined the group of pregnant women based on the timing of their pregnancy 
and HAART initiation.  We did not find any significant difference in immunological response 
and virological response.  Contrasting results were found in a study using self-reporting to 
measure adherence among American women, this study found that high adherence was 
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significantly associated with pregnancy before starting HAART (Bardeguez et al., 2008).  In 
contrast, a pharmacy claims-based analysis of American women found that women who 
became pregnant while on HAART showed better adherence compared to women who first 
took HAART during pregnancy (Laine et al., 2000).   These studies were conducted in 
resource-rich settings.  Possibly women who were pregnant and eligible to initiate 
treatment during pregnancy are given guidance on the importance of adherence to HAART 
for the health of the baby upon prescription of the therapy.  These women may have time 
to invest in their baby and develop an emotional connection before they start therapy, 
giving them incentive and motivation to adhere.  In our study, we found that pregnant 
women were ‘fast tracked’ onto ARV treatment in an effort to curb further 
immunodeficiency, and to prevent mother-to-child transmission.  However, fast tracking 
these women may have deprived them from coming to terms with their HIV status and 
treatment readiness.  Particular concerns exists around how patient preparation before 
HAART initiation influences long-term outcomes.  There is an urgent need to educate and 
enrol pregnant women sooner onto triple therapy. 
 
5.3 LOSS TO FOLLOW-UP 
 
Women pregnant at start of HAART and women pregnant after starting HAART are both 
found to be significantly associated with being lost to follow-up at 3 months and 6 months 
after HAART initiation.  In additions age at initiation, baseline CD4 cell count and 
employment status were strongly associated with being lost to follow-up at both 3 months 
and 6 months.  Being lost to follow-up within 6 months after initiating HAART in our study is 
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consistent with the loss to follow-up identified in the general population in studies 
conducted in sub-Saharan Africa (Lawn et al., 2006; Dalal et al., 2008; Kaplan et al., 2008).  
 
In this study we looked at the loss to follow-up rate of women enrolled in an urban 
antiretroviral treatment programme in a resource-limited setting.   Over a period of 3 years 
the cumulative programmatic lost to follow-up was 25 %.  An interesting trend was 
observed in the loss to follow-up rate, where we found 10% women pregnant after starting 
HAART, 24.1 % non pregnant women and 41.1 % women pregnant at start of HAART to be 
loss to follow-up.   This observation indicates almost a doubling trend across the three 
different groups of women (10%, 24.1% and 41.2%).   
 
The high loss to follow-up rate for pregnant women in this study is consistent with the 
findings presented by Kaplan et al (2008).  Kaplan et al (2008) reported lost to follow up rate 
of 32% pregnant women compared to 13% not pregnant over 3 years on treatment in a 
retrospective analysis of 2131 women referred for treatment to the Hannan Crusaid 
Treatment Centre in Gugulethu.  Kaplan defined on-treatment loss to follow-up as patients 
receiving ART who had not attended the clinic for 12 or more weeks.  This definition is 
consistent with our definition.   
 
In ART programmes, loss to follow-up rates have been shown to be influenced by 
programmatic characteristics, with the provision of a free service and a comprehensive 
treatment support system identified as contributing to higher patient retention (Rosen et 
al., 2007; Lawn et al., 2007). 
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Inadequate adherence or discontinuation of treatment raises serious public health concerns 
that negate much of the benefits and effectiveness of treatment programmes.  From the 
literature review of studies on patient retention it is found that most of the deaths and 
attrition occurs in the first six months after initiating treatment (Rosen et al., 2007).   This 
highlights a need for better programmatic support and close monitoring in the initial 
months after starting HAART and maybe HAART should be initiated where ANC is provided.   
 
Another important aspect that growing antiretroviral treatment programmes are facing is 
the shortage of resources like staff and infrastructure to cope with the ever increasing 
population requiring treatment, care and support (Rosen et al., 2007).   These constraints do 
have a negative impact on patient care and patient retention.  Treating a maximum number 
of new patients has been the top priority of many public sector programmes, with little 
documentation and tracing interventions to follow-up patients who miss visits and default 
treatment.   
 
5.4 MORTALITY 
 
Age at initiation, baseline CD4 cell count and baseline tuberculosis were found to be 
significantly associated with mortality. The overall mortality for the cohort was 4.8% ( 248 
deaths) over the three year study period.   In our analysis the highest rate of death was 
found among the not pregnant group followed by the women pregnant at start.  The not 
pregnant group were significantly older (F=202.82, p=<0.001) than the women pregnant at 
start of HAART and the women pregnant after HAART initiation. Therefore these women 
may be faced with other underlying conditions which further compromise the immune 
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system (NCCDEM, 2004-2005).    Women who became pregnant after initiating HAART 
showed the lowest rate of death compared to the other two groups.  Women who were 
pregnant at start of HAART were five times less likely to die compared to women who 
became pregnant after initiating HAART who were three times less likely to die compared to 
the women who were not pregnant. Low CD4 cell count and an advanced WHO stage at 
baseline were strong predictors of death.  This confirms that women who were not 
pregnant were assessing treatment at an advance stage of the HIV disease, thus having an 
already compromised immune system.  Moreover, our results show that > 30% not 
pregnant women had a WHO stage III and >10% had WHO stage IV at initiation.  A CD4 cell 
count <200 cell/mm3 is the threshold where the risks of opportunistic infections 
dramatically increase thus increasing the risks of mortality (National Treatment Guideline, 
2004). 
 
Delay in seeking help is the most common patient related avoidable factor seen from the 
low baseline immune status in our study across all groups of women.  The exact meaning of 
this is difficult to establish as lack of transport or other factors inhibiting the woman seeking 
help is not recorded in the electronic system.  
 
Pregnant women mainly learn their serostatus at the antenatal clinic.  According to the 
review by NCCEMD (2004-2005), lack of attendance at antenatal clinics continues to be a 
common patient related avoidable factor and health messages must continue to stress the 
need to attend antenatal clinic early in pregnancy.  
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Our study suggests that greater attention needs to be paid to the quality of antenatal care 
and HIV management so that opportunities are not missed in reducing loss to follow-up and 
mortality in this sub-group of the population. This is comparable with the review given in 
the Saving Mothers report (NCCEMD 2004-2005), particularly relevant to HIV infected 
women, women with hypertension or other pre-existing medical conditions. 
 
5.5 OUTCOMES AFTER THE INTRODUCTION OF TRACING INTERVENTION 
 
Women in our study initiated ART at different times over the three year study period.  
Therefore not all women were at risk at the same time for becoming loss to follow-up. The 
tracing intervention was implemented in April 2007.  Women, who initiated treatment 
before the 31st March 2007, were at risk from the time they enrolled on the study until 31st 
March and women who initiated treatment in the time period after the 31st March 2007 
were at risk from there on until the end of the study.  However, those women that span the 
31st March timeline, where at risk for longer.   Also the period before the intervention was 
much longer then the time period between the implementation of the tracing intervention 
and the end of our study. Hence the short period of 9 months was not long enough to 
evaluate the success of the intervention.    
 
However, tracing did help in finding out some details of the patients (Table 11b) that were 
transferred out to another facility, and also details of patients whose death was never 
reported to the clinic.  Moreover, those that could not be found after tracing were 
confirmed loss to follow-up.  Compared to the not pregnant women and the women 
pregnant after HAART initiation, a higher percentage of women pregnant at start were 
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confirmed to be lost to follow-up.  Tracing intervention also confirmed that pregnancy is 
strongly related to becoming loss to follow-up, with a larger majority of the women 
pregnant at start of HAART compared to the women pregnant after HAART and the not 
pregnant women.  This construes that among the pregnant women those fast tracked onto 
treatment are at higher risk of becoming loss to follow-up. 
 
Patients who could not be found after tracing were due to the poor demographic data 
recorded in the electronic case files. It is unclear whether patients provided incorrect 
contact details due to fear of disclosure or whether the details obtained by the clinic staff 
were inadequate.  This is a serious concern as contact information that is incorrect, out 
dated or not available could relate to the risk of disease progression leading to death.  The 
patients that are too ill and weak may not be able to come to the clinic.  Another aspect is 
the time lapse between being lost to follow up and actual tracing.    Moreover in an urban 
environment, it is generally difficult to trace mobile patients.  Moreover, home visit tracing 
could prove to be rather costly, therefore the emphasis should be on prevention of lost to 
follow up.  Our study suggests that telephone tracing soon after a missed appointment may 
reduce the treatment default gap.   By reducing LTFU, adherence would indirectly be 
improved which is a key in HAART care. 
 
Death that was recorded for patients after the tracing intervention was implemented, used 
the date the information was identified by the community tracers as the death date.  
Therefore there may have been deaths that occurred prior to the implementation of the 
tracing intervention but because the death was not reported to the clinic there was no 
record in the patients’ electronic file.  Thus a sudden rise in the number of deaths after the 
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tracing intervention is noticed.  Majority of the deaths may have occurred shortly after the 
initiation of HAART.  This is due to the severely compromised immune system that could not 
show much response to antiretroviral treatment.  Low baseline CD4 cell count and poor 
immunological response after starting HAART is attributed to this assumption.  
 
Our study showed that becoming loss to follow-up was strongly associated with being 
pregnant.  Being pregnant, baseline CD4 cell count, age and unemployment were found to 
be significantly associated in both bivariate and multivariate analysis.   
 
This is a huge public health concern as the outcome of these untraced pregnant women 
could not be determined.  This again underestimates the mortality rate in the pregnant 
women.   The high lost to follow up rate in this sub group of the population is of particular 
concern as it not only has an impact on the morbidity and mortality of the mother but also 
more likely to increase the risk of mother to child transmission and the development of 
resistant HIV strains.   Orphaning due to the lost of a primary caretaker is another public 
health concern. 
 
5.7 LIMITATIONS 
 
This study had the following limitations:  
 
Although much effort is focused on the collection and capturing of data at Themba Lethu 
Clinic, the accuracy of the collected data could not be verified against any source due to the 
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de-identified nature of the data. Moreover, missing data in particular, the precision of the 
data of deceased patients was largely dependent on verbal feedbacks from family members 
or friends.  This could not be cross referenced with the national death register for 
ascertainment of death dates.   
 
Another limitation is we did detailed analysis of 3 and 6 months for immunological and 6 
months for virological response but the international indicator seems to be 1 year.  We 
could not do the analyses for twelve months due to a large amount of missing data. 
Furthermore, our loss to follow-up definition did not seem to apply exactly the same 
throughout as some of the women where more actively traced.   
 
One limitation of the study is the study period.  There was not much time to evaluate the 
introduction of the proactive tracing.  The tracing intervention was introduced in April 2007 
and the study ended in December 2007.   Therefore the time period for the risk to become 
loss to follow-up faced by the patients who started treatment prior April 2007 was not the 
same compared to the time period for the risk to become loss to follow-up faced by those 
patients that initiated treatment after April 2007 until the end of the study.  Therefore the 
time to evaluate the true outcome the tracing intervention was far too short. 
Identifying the factors that put the different groups of women at risk for poor adherence is 
essential in targeting appropriate interventions.  In our study adjusted analysis showed only 
a few factors associated with adherence and lost to follow up.  Demographic data like 
income, marital status, socio-economic status, and education level and disclosure status 
have been identified from literature review as significant variables associated with 
adherence and lost to follow up rates. However these data were unavailable to us as they 
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are not routinely collected.  Another limitation was additional information on baseline 
opportunistic infections was not available and therefore could not be controlled for in any 
of the analyses.   
 
As this study was a retrospective analysis, the actual reasons for patients defaulting 
treatment and not returning to the clinic could not be established.  The reason for reviewing 
the data of all women enrolled at Themba Lethu Clinic between January 2005 and 
December 2007 is that the clinic began to enrol female patients referred from the 
Coronation Women and Children’s Hospital since January 2005.  Moreover this clinic uses an 
electronic data system in real time in one of the largest public antiretroviral rollout site that 
is representative of urban population with a database with up-to-date longitudinal data.    
 
To improve the quality of data, the lay counsellors and reception clerks need to be trained 
and educated to have a better understanding of the importance of correct contact 
information.   Also from a data management perspective it is vital to understand that input 
of poor quality data, means poor outputs and evaluations.  “Garbage in is garbage out” 
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CHAPTER 6 CONCLUSION AND RECOMMENDATIONS 
 
To our knowledge this is one of the first studies of HAART adherence and loss to follow-up 
of pregnant women in sub-Saharan Africa.  Moreover the clinical database at Themba Lethu 
Clinic is one of the biggest databases using a real time patient health management system.  
Therefore the findings are quite persuasive as they are from a rich cohort that is 
representative of an urban population accessing antiretroviral therapy in the public sector.  
 
The strong association of pregnancy to adherence and loss to follow-up is of particular 
concern as it will not only impact on the morbidity and the mortality of the mother, but also 
is likely to result in an increased risk of HIV transmission to the child and a high possibility of 
transmission of resistant viral strain.  This analysis points to the urgent need for a more 
focused intervention to identify why this sub-group of the population is at high risk of 
defaulting treatment.  It also identifies that pregnant women requires additional 
longitudinal interventions for programmatic retention.   There is an urgent priority to 
strengthen our health system with the integration of antenatal care and HIV services. 
 
We therefore need strategies in large cohorts to improve education levels which could help 
improve treatment denial and in turn improve patient retention. Tracing via telephone may 
have its own challenges due to the ever changing mobile phone numbers, and home visit 
may be far too costly and difficult in both urban areas and informal settlements.    This study 
suggests that improvement in pre-treatment counselling with special focus to pregnant 
women coupled with education and continuous adherence support during treatment would 
improve the management of patients in large cohorts and also the outcome of treatment 
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programmes.   One of the major challenges of telephone tracing and home visits are the 
errors in collecting accurate data, the low rate of literacy of our lay counsellors and the 
intensive supervision of accurate data entry.  Therefore training and educating the frontline 
administrators in understanding the importance of correct contact information may 
significantly improve the rates of tracing and decrease the loss to follow-up rates. 
 
Mortality within the first few months after HAART initiation may be due to the late stage at 
which many patients present for treatment, this indicates the need for early initiation and 
better tracing interventions to follow-up lost to initiation.    Antiretroviral services should be 
integrated with primary health care services thus allowing an opportunity for a larger 
number of women to know their serostatus earlier and access treatment with higher CD4 
cell count and less advanced HIV disease. 
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